18Rift Valley fever virus (RVFV) is an emerging, mosquito-borne, zoonotic pathogen 19 with recurrent outbreaks paying a considerable toll of human deaths in many African 20 countries, for which no effective treatment is available. In cell culture studies and with 21 laboratory animal models, the nucleoside analogue favipiravir (T-705) has demonstrated 22 great potential for the treatment of several seasonal, chronic and emerging RNA virus 23 infections of humans, suggesting applicability to control some viral outbreaks. 24 Treatment with favipiravir was shown to reduce the infectivity of Rift Valley fever virus 25 both in cell cultures and in experimental animal models, but the mechanism of this 26 protective effect is not understood. In this work we show that favipiravir at 27 concentrations well below the toxicity threshold estimated for cells is able to extinguish 28 RVFV from infected cell cultures. Nucleotide sequence analysis has documented RVFV 29 mutagenesis associated with virus extinction, with a significant increase in G to A and C 30 to U transition frequencies, and a decrease of specific infectivity, hallmarks of lethal 31 mutagenesis. 33 Rift Valley fever virus (RVFV) is a mosquito-borne bunyavirus belonging to the 34 recently reclassified phlebovirus genus (Family Phenuiviridae, Order Bunyavirales). 35 RVFV causes an important disease in ruminants often transmitted to humans after the 36 occurrence of epizootic outbreaks. Although the disease has been reported only in 37 African countries with some incursions in the Middle East and Indian Ocean islands, 38 there are concerns for its potential spread to other locations, including Europe (1, 2).
39Currently, there is no available treatment or licensed RVF vaccine in Europe, therefore 40 the development of effective control strategies is an essential field of research. The use 41 of antiviral agents for treatment in livestock is generally not affordable, although it is 42 often being proposed for viral veterinary diseases as a strategy to fill the gap between 43 the time of the infection and the effective development of the host immune response (3, 44 4). In contrast, in the case of humans infected or at risk of infection with RVFV, 45 antiviral treatment is fully warranted. Antiviral base and nucleoside analogues effective 46 against RVFV are available (5-7). Among the nucleoside analogs exerting anti-RVFV 47 activity, ribavirin [1-β-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide], favipiravir 48 [6-fluoro-3-hydroxy-2-pyrazinecarboxamide] and more recently BCX4430 49 [(2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-50 (hydroxymethyl)pyrrolidine-3,4-diol] (Galidesivir) have been described (6-8). 51 Particularly, favipiravir displays potent antiviral activity against different RNA viruses 52 (9-16). Upon cell intake, favipiravir is converted by cellular enzymes into its active 53 form (favipiravir-4-ribofuranosyl-5-triphosphate), which functions as a purine 54 nucleotide analogue. Favipiravir can act as an RNA chain terminator...